Literature DB >> 12815486

Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting.

F Yoshiba1, M Hagihara, K Tazume, Y Ogawa, K Kishi, A Higuchi, S Kato, T Hotta.   

Abstract

A patient with chronic active Epstein-Barr virus (EBV) infection was treated by allogeneic SCT from an HLA-identical sibling donor, using a nonmyeloablative regimen. Even on day 70, mixed chimerism remained together with a quite high viral load. On days 76 and 90, donor lymphocytes were infused after short-term culture with OKT3 plus recombinant IL-2. At 8 days after the last dose, all hematopoietic cells were shown to be donor-type dominant; thereafter, the viral load started to decrease and finally disappeared. Anti-mHA-specific CTLs were generated in vitro, which were shown to be effective in eradicate viral-infected recipient T lymphocytes.

Entities:  

Mesh:

Year:  2003        PMID: 12815486     DOI: 10.1038/sj.bmt.1704074

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Authors:  Ayako Arai; Ken-Ichi Imadome; Yuko Watanabe; Mayumi Yoshimori; Takatoshi Koyama; Takeharu Kawaguchi; Chiaki Nakaseko; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2011-04-14       Impact factor: 2.490

2.  Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active epstein-barr virus infection.

Authors:  Masao Nakagawa; Satoshi Hashino; Mutsumi Takahata; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Sachiko Ando; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

3.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

4.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06

Review 5.  Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.

Authors:  Claudio Annaloro; Fabio Serpenti; Giorgia Saporiti; Giulia Galassi; Francesca Cavallaro; Federica Grifoni; Maria Goldaniga; Luca Baldini; Francesco Onida
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.